CD31 acts as a co-inhibitory receptor, where CD31+ DCs are more tolerogenic, suggesting in the absence of FGL2 cDC2s in B16F10 tumours are more activated (MHCII+, CD86+, CD40+) and less immunosuppressive (CD31+). Here, PECAM1 is linked to neoplasm.